Watson Boosts Women’s Health Holdings In $305M Uteron Deal

Law360, New York (January 23, 2013, 3:32 PM EST) -- Watson Pharmaceuticals Inc. has acquired Uteron Pharma SA in a deal valued at $305 million with the strategic goal of expanding the Parsippany, N.J.-based company's women’s health products, according to a statement released Wednesday.

Watson will pay $150 million in cash up front for Uteron, then will pay up to $155 million in potential future milestone payments, the statement says. By acquiring Uteron, which is based in Belgium, Watson will be able to market the products in Uteron’s pipeline, including a long-term contraceptive device and a...
To view the full article, register now.